Stay updated with breaking news from Eric Widera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A second Alzheimer's drug comes after first drug made a historical breakthrough in the treatment of the disease earlier in the month.
(CNN) — The full approval this month of the Alzheimer’s drug Leqembi marked a historic shift in the treatment of the disease: For the first time, doctors have<a class="excerpt-read-more" href="https://whdh.com/news/second-alzheimers-drug-to-slow-diseases-progression-may-be-approved-in-the-us-this-year/">Read More</a>
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease.
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.